
The objective of this article is to offer a critical analysis of policies and practices concerning consent and refusal of electroconvulsive therapy (ECT) in terms of their compliance with the legal principles concerning consent to treatment. Using the province of Quebec, Canada, as a case study, we first identified consenting documents and court orders for ECT treatments; we then critically appraised them using National Institute for Health and Care Excellence guidelines on ECT as a gold standard. We find that consent documents suffer lack of clarity and transparency regarding ECT’s medical indication, risks, and benefits. The review of court orders reveals a paucity of information pertaining to the diagnosis, clinical indications, benefits, and potential risks associated with ECT for patients who lack the capacity for consent.
A retrospective sample of 20 adolescents without a history of psychosis was divided into two equal groups of 10: one with daily use of cannabis for 6 or more months and one without any history of cannabis or other substance use. The groups were matched on both sex and age. All 20 adolescents were administered the Rorschach Performance Assessment System (R-PAS), which were all determined to be valid protocols. A series of eight independent samplettests with Cohen’sdeffect sizes were done, along with other descriptive and inferential statistics. Results showed that seven of eight perception and thinking R-PAS variables reliably distinguished between the Cannabis and No Cannabis groups. Further, the Cannabis group showed standard scores falling within either the very high or extremely high interpretive categories for this test, hence manifesting unequivocal signs of psychotic disturbance as operationally defined by the perception and thinking R-PAS variables. Further, the Cannabis group scored approximately two to three standard deviation differences on these R-PAS variables versus the No Cannabis group, hence manifesting consistently large effects. Implications of these findings were discussed, including some limitations of the present study and suggestions for future research.
Prior to the release of the selective serotonin reuptake-inhibiting (SSRI) drugs as antidepressants, serotonin reuptake-inhibiting drugs were known to have marked effects on sexual function, but these effects were not laid out in drug labels. After the launch of SSRIs, concerns were raised about possible effects on fertility, but these effects are not laid out in the labels of these medicines. This paper charts the evolution of our knowledge in these domains and social and institutional responses to that knowledge. Given the gravity of conditions like post-SSRI sexual dysfunction, the effect of sexual dysfunction not just on individuals taking these drugs but on their partners, the increased use of these drugs among adolescents, and a possible contribution to falling fertility rates, this article asks if there are clinical and societal matters here that should now be more openly discussed.
This article argues that the pharmaceutical industry uses psychological techniques focusing on social conditioning, shame, and guilt to sell its concepts and products to an ever-widening group of health care professionals. Clinical psychology shows signs of both joining and resisting this process.